Health

The treatment of unresectable liver cancer has long been a challenge in the medical field. However, a recent randomized trial called EMERALD-1 has shown promising results in improving outcomes using transarterial chemoembolization (TACE) in combination with immunotherapy. This article will analyze the trial and its implications for the treatment of hepatocellular carcinoma (HCC). The EMERALD-1